BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33288848)

  • 1. Stem cell characteristics promote aggressiveness of diffuse large B-cell lymphoma.
    Chang KC; Chen RY; Wang YC; Hung LY; Medeiros LJ; Chen YP; Chen TY; Yang JC; Chiang PM
    Sci Rep; 2020 Dec; 10(1):21342. PubMed ID: 33288848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.
    Cui W; Zheng S; Li X; Ma Y; Sang W; Liu M; Zhang W; Zhou X
    Tumour Biol; 2016 Sep; 37(9):12767-12777. PubMed ID: 27448819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma].
    Wu L; Zhang YZ; Xia B; Li XW; Yuan T; Tian C; Zhao HF; Yu Y; Sotomayor E
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1036-1042. PubMed ID: 29365396
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
    Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
    J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA‑196a‑3p inhibits cell proliferation and promotes cell apoptosis by targeting ADP ribosylation factor 4 in diffuse large B‑cell lymphoma.
    Fu J; Lou X; Wan S; Zhao X; Chen Z; Zhu M; Guo L; Wu D; Wang S
    Oncol Rep; 2021 Feb; 45(2):764-775. PubMed ID: 33416178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.
    Bentayeb H; Aitamer M; Petit B; Dubanet L; Elderwish S; Désaubry L; de Gramont A; Raymond E; Olivrie A; Abraham J; Jauberteau MO; Troutaud D
    J Exp Clin Cancer Res; 2019 Nov; 38(1):450. PubMed ID: 31684984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between Chemotactic Factor CCL5 and Diabet-associated Diffuse Large B Cell Lymphoma].
    Zhang JC; Liu FR; Hu HX; He F; Tu Y; Wei B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1325-30. PubMed ID: 26524031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
    Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
    Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large B cell lymphoma presenting initially in bone marrow, liver and spleen: an aggressive entity associated frequently with haemophagocytic syndrome.
    Yeh YM; Chang KC; Chen YP; Kao LY; Tsai HP; Ho CL; Wang JR; Jones D; Chen TY
    Histopathology; 2010 Dec; 57(6):785-95. PubMed ID: 21166693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
    Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ
    Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.
    Kim SW; Oleksyn DW; Rossi RM; Jordan CT; Sanz I; Chen L; Zhao J
    Blood; 2008 Feb; 111(3):1644-53. PubMed ID: 18025152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
    Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
    Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels.
    Zhong W; Zhu Z; Xu X; Zhang H; Xiong H; Li Q; Wei Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):73. PubMed ID: 30755239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
    Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
    Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex.
    Dai YH; Hung LY; Chen RY; Lai CH; Chang KC
    Transl Res; 2016 Sep; 175():129-143.e13. PubMed ID: 27150054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
    Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
    Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link.
    Kuttler F; Valnet-Rabier MB; Angonin R; Ferrand C; Deconinck E; Mougin C; Cahn JY; Fest T
    Leukemia; 2002 Apr; 16(4):726-35. PubMed ID: 11960356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.